Related Experiment Video
Updated: Jan 30, 2026

The In ovo CAM-assay as a Xenograft Model for Sarcoma
Published on: July 17, 2013
The antitumor efficacy of monomeric disintegrin obtustatin in S-180 sarcoma mouse model
Narine Ghazaryan1,2, Naira Movsisyan3,4, Joana Catarina Macedo5
1Laboratory of Toxinology and Molecular Systematics, L.A. Orbeli Institute of Physiology, 0028, Yerevan, Armenia. naringhazaryan@gmail.com.
Abstract:
Obtustatin, isolated from the Levantine Viper snake venom (Macrovipera lebetina obtusa -MLO), is the shortest known monomeric disintegrin shown to specifically inhibit the binding of the α1β1 integrin to collagen IV. Its oncostatic effect is due to the inhibition of angiogenesis, likely through α1β1 integrin inhibition in endothelial cells. To explore the therapeutic potential of obtustatin, we studied its effect in S-180 sarcoma-bearing mice model in vivo as well as in human dermal microvascular endothelial cells (HMVEC-D) in vitro, and tested anti-angiogenic activity in vivo using the chick embryo chorioallantoic membrane assay (CAM assay). Our in vivo results show that obtustatin inhibits tumour growth by 33%. The expression of vascular endothelial growth factor (VEGF) increased after treatment with obtustatin, but the level of expression of caspase 8 did not change. In addition, our results demonstrate that obtustatin inhibits FGF2-induced angiogenesis in the CAM assay. Our in vitro results show that obtustatin does not exhibit cytotoxic activity in HMVEC-D cells in comparison to in vivo results. Thus, our findings disclose that obtustatin might be a potential candidate for the treatment of sarcoma in vivo with low toxicity.
Insights
Obtustatin, a snake venom peptide, shows promise in treating sarcoma by inhibiting tumor growth and angiogenesis. This disintegrin demonstrated significant anti-cancer effects in mice with low toxicity.
Area of Science:
- Biochemistry
- Pharmacology
- Oncology
Background:
- Obtustatin is a short monomeric disintegrin from Levantine Viper snake venom (Macrovipera lebetina obtusa - MLO).
- It specifically inhibits the α1β1 integrin-collagen IV interaction.
- Its oncostatic effect is linked to inhibiting angiogenesis via α1β1 integrin in endothelial cells.
Purpose of the Study:
- To explore the therapeutic potential of obtustatin for sarcoma treatment.
- To evaluate its anti-angiogenic and anti-tumor effects in vitro and in vivo.
Main Methods:
- In vivo studies using S-180 sarcoma-bearing mice.
- In vitro studies on human dermal microvascular endothelial cells (HMVEC-D).
- Chick embryo chorioallantoic membrane (CAM) assay for anti-angiogenic activity.
Main Results:
- Obtustatin inhibited tumor growth by 33% in vivo.
- Vascular endothelial growth factor (VEGF) expression increased post-treatment; caspase 8 levels remained unchanged.
- Obtustatin inhibited FGF2-induced angiogenesis in the CAM assay and showed no cytotoxicity in HMVEC-D cells.
Conclusions:
- Obtustatin demonstrates significant anti-tumor and anti-angiogenic activity.
- It may be a potential therapeutic candidate for sarcoma treatment with low toxicity.
Related Concept Videos
Self-Efficacy
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Dose-Response Relationship: Potency and Efficacy
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Molecular Models
The Bohr Model

